Merck Will Allow Other Drug Manufacturers to Produce Its COVID-19 Pill
(LONDON) —Pharmaceutical company Merck agreed to allow other drug makers to produce its COVID-19 pill, in a move aimed at helping millions of people in poorer countries get access to the potentially life-saving drug, a United Nations-backed public health organization said on Wednesday. The Medicines Patent Pool said in a statement that it had signed a voluntary licensing agreement for molnupiravir with Merck and its partner Ridgeback Biotherapeutics. The agreement will allow the Medicines Patent Pool to grant further licenses to qualified companies who are approved to make the drug. Neither drug maker will receive ro...
Source: TIME: Health - October 27, 2021 Category: Consumer Health News Authors: Associated Press Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news

European Medicines Agency's Committee for Medicinal Products for Human Use starts rolling review of molnupiravir for treatment of COVID-19 in adults, EMA
Decision to start rolling review of this oral antiviral medicine is based on preliminary results from lab and clinical studies suggesting it may reduce ability of SARS CoV 2 to multiply in the body, thereby preventing hospitalisation or death in patients with COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 27, 2021 Category: Consumer Health News Source Type: news

European Medicines Agency's Committee for Medicinal Products for Human Use recommends booster dose of Moderna's COVID-19 vaccine, Spikevax , EMA
This follows data showing that a booster, consisting of half the dose used for primary vaccination, given 6 to 8 months after 2nd dose, led to a rise in antibody levels in adults whose antibody levels were waning, with a pattern of side effects similar to that after 2nd dose. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 27, 2021 Category: Consumer Health News Source Type: news

EU drug regulator OKs booster doses of Moderna's COVID shot
The European Medicines Agency said a booster dose of Moderna’s coronavirus vaccine “can be considered” in people aged 18 and above (Source: ABC News: Health)
Source: ABC News: Health - October 25, 2021 Category: Consumer Health News Tags: Health Source Type: news

Merck asks EU regulator to authorize pill that treats COVID
Pharmaceutical company Merck has asked the European Medicines Agency to authorize its COVID-19 antiviral treatment (Source: ABC News: Health)
Source: ABC News: Health - October 25, 2021 Category: Consumer Health News Tags: Health Source Type: news

European Medicines Agency starts rolling review of Evusheld (tixagevimab and cilgavimab) for prevention of Covid-19 in adults, EMA
Tixagevimab and cilgavimab are monoclonal antibodies that attach to the spike protein of SARS-CoV-2 and stop the virus from entering the body's cells and causing infection. The decision to start the rolling review was based on preliminary results from clinical studies. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 18, 2021 Category: Consumer Health News Source Type: news

EU Panel Likes Two Cancer Drugs, Drops One EU Panel Likes Two Cancer Drugs, Drops One
Two new cancer drugs were recommended for approval, and one had its marketing authorization withdrawn at the October meeting of the European Medicines Agency's advisory panel.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

The Latest: Europe Medicines Agency looking at antibody drug
The European Medicines Agency has started an expedited licensing process for an antibody combination drug aimed at preventing the coronavirus, made by AstraZeneca (Source: ABC News: Health)
Source: ABC News: Health - October 14, 2021 Category: Consumer Health News Tags: Health Source Type: news

Roche ’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter 90-minute Gazyvaro ® (obinutuzumab) infusion time, administered in combination with chemotherapy in patients with previously treated or untreated advanced follicular lymphoma (FL). (Source: Roche Investor Update)
Source: Roche Investor Update - October 14, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter 90-minute Gazyvaro ® (obinutuzumab) infusion time, administered in combination with chemotherapy in patients with previously treated or untreated advanced follicular lymphoma (FL). (Source: Roche Media News)
Source: Roche Media News - October 14, 2021 Category: Pharmaceuticals Source Type: news

Covid vaccine side effects: Stay 'alert' to three new side effects - EMA issues warning
THE SIDE effects of the Covid vaccines continue to be monitored stringently as booster programmes get underway. The European Medicines Agency today has issued instructions to healthcare professionals administering the Janssen vaccine, which is approved for UK use. The EMA urges professionals to stay "alert" to three serious side effects following vaccination. (Source: Daily Express - Health)
Source: Daily Express - Health - October 13, 2021 Category: Consumer Health News Source Type: news

Pfizer Booster Can Be Given After 6 Months, European Drug Agency Says
The E.U. ’s main drug regulator also said that extra doses of the Moderna and Pfizer-BioNTech vaccines can be given to those with underlying health conditions as early as 28 days after the second dose. (Source: NYT)
Source: NYT - October 4, 2021 Category: American Health Authors: Monika Pronczuk Tags: Vaccination and Immunization Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) European Medicines Agency Source Type: news

Pfizer and BioNTech receive CHMP positive opinion for COVID-19 vaccine booster in the European Union
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies' COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18 years of age and older. (Source: World Pharma News)
Source: World Pharma News - October 4, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential ben...
Source: Roche Investor Update - September 24, 2021 Category: Pharmaceuticals Source Type: news

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential ben...
Source: Roche Media News - September 24, 2021 Category: Pharmaceuticals Source Type: news

Flurry of Cancer Drug Endorsements From EU Panel Flurry of Cancer Drug Endorsements From EU Panel
The European Medicines Agency panel recommended for approval three new cancer drugs and additional indications for two other already marketed immunotherapies.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche receives positive CHMP opinion for Gavreto ® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated w ith a RET inhibitor. (Source: Roche Media News)
Source: Roche Media News - September 17, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Gavreto ® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated w ith a RET inhibitor. (Source: Roche Investor Update)
Source: Roche Investor Update - September 17, 2021 Category: Pharmaceuticals Source Type: news

Ivermectin: Cochrane ’s most talked about review so far, ever. Why?
In this author interview with Stephanie Weibel and Maria Popp, we find out more about their Cochrane review, Ivermectin for treating and preventing COVID-19. The review currently has an Altmetric Attention Score of more than 7000, which makes it the most talked-about review in the history of the Cochrane Library.Briefly, what is Ivermectin?Ivermectin is a medicine used to kill parasites, such as intestinal worms (helminths) in animals or scabies in humans. It is inexpensive and it is widely used in regions of the world where parasitic infestations are common, such as in parts of Asia and South America. Ivermectin has few u...
Source: Cochrane News and Events - September 14, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news

EMA issues 'warning' about new 'serious' side effect of the AstraZeneca Covid vaccine
THE EUROPEAN Medicines Agency has added a rare but serious condition to its product information for the AstraZeneca Covid vaccine. The regulatory body has issued a warning that a "causal relationship" to the vaccine is a "reasonable possibility". (Source: Daily Express - Health)
Source: Daily Express - Health - September 10, 2021 Category: Consumer Health News Source Type: news

AstraZeneca's Covid jab can trigger nerve disorder Guillain-Barre syndrome, EU says
The European Medicines Agency said they considered it to be 'at least a reasonable possibility' that the AstraZeneca jab could trigger the condition in 'very rare' cases. (Source: the Mail online | Health)
Source: the Mail online | Health - September 9, 2021 Category: Consumer Health News Source Type: news

Pfizer and BioNTech submit a variation to EMA with the data in support of a booster dose of COMIRNATY ®
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Conditional Marketing Authorization (CMA) with data supporting a booster (third) dose of COMIRNATY® (COVID-19 vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older. (Source: World Pharma News)
Source: World Pharma News - September 9, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

AstraZeneca vaccine side effects: Four new side effects reported - EMA issues major update
THE UNPRECEDENTED scale and speed of the global vaccination effort has required health bodies to constantly monitor for vaccine side effects. On Tuesday, the European Medicines Agency added four new side effects to the product information for the AstraZeneca Covid vaccine. A causal link has not been specified, however. (Source: Daily Express - Health)
Source: Daily Express - Health - September 8, 2021 Category: Consumer Health News Source Type: news

EU regulator evaluating if COVID vaccine booster is needed
The European Medicines Agency says it has started an expedited evaluation on whether to recommend use of a booster dose of the coronavirus vaccine made by Pfizer-BioNTech (Source: ABC News: Health)
Source: ABC News: Health - September 6, 2021 Category: Consumer Health News Tags: Health Source Type: news

European Centre for Disease Prevention and Control (CDC) and European Medicines Agency (EMA) issue joint update for additional and booster doses of COVID-19 vaccines, EMA (published 2nd September 2021)
Based on current evidence, there is no urgent need for administration of booster doses of vaccines to fully vaccinated individuals. The report notes additional doses should already be considered for those with severely weakened immune systems as part of their primary vaccination (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 3, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 25, 2021 – Johnson & Johnson today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine. In July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization. In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals...
Source: Johnson and Johnson - August 25, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Moderna COVID-19 vaccine approved by MHRA for use in adolescents, MHRA
This extension to the current UK approval of the Moderna (Spikevax) vaccine covers use in 12- to 17-year-olds. The vaccine was authorised for use in 12-17 year olds in Northern Ireland on 23 July via the approval from the European Medicines Agency. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 19, 2021 Category: Consumer Health News Source Type: news

Pfizer and BioNTech announce submission of initial data to U.S. FDA to support booster dose of COVID-19 vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies' COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks. (Source: World Pharma News)
Source: World Pharma News - August 16, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

EMA investigating link between Pfizer and Moderna vaccines and three new conditions
THE PFIZER and Moderna Covid vaccines have been integral to turning the tide on the pandemic in the UK and beyond. The efficacy of the vaccines far outweigh the vanishingly small risk of developing a complication, but three new conditions have been linked to the Covid vaccines. The European Medicines Agency is actively investigating the link. (Source: Daily Express - Health)
Source: Daily Express - Health - August 15, 2021 Category: Consumer Health News Source Type: news

ECDC and EMA update on COVID-19, EMA
Full vaccination is key to protecting against serious COVID-19, including disease caused by the Delta variant. With the increasing circulation of the Delta variant of SARS-CoV-2 in EU/EEA countries, the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) strongly encourage those who are eligible for vaccination but have not yet been vaccinated to start and complete the recommended COVID-19 vaccination schedule in a timely manner. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 9, 2021 Category: Consumer Health News Source Type: news

FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growt...
Source: Roche Media News - July 29, 2021 Category: Pharmaceuticals Source Type: news

FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growt...
Source: Roche Investor Update - July 29, 2021 Category: Pharmaceuticals Source Type: news

Data for Roche ’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
Basel, 29 July 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH Part 2, a pivotal global study evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies aged 1-7 months old with symptomatic Type 1 spinal muscular atr ophy (SMA). The study met its primary endpoint with 29% of infants (12/41) sitting without support for at least five seconds* by month 12, a milestone not seen in the natural course of the disease. Safety for Evrysdi in the FIREFISH Part 2 study was consistent with its known safety profile.“With...
Source: Roche Media News - July 29, 2021 Category: Pharmaceuticals Source Type: news

Data for Roche ’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
Basel, 29 July 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH Part 2, a pivotal global study evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies aged 1-7 months old with symptomatic Type 1 spinal muscular atr ophy (SMA). The study met its primary endpoint with 29% of infants (12/41) sitting without support for at least five seconds* by month 12, a milestone not seen in the natural course of the disease. Safety for Evrysdi in the FIREFISH Part 2 study was consistent with its known safety profile.“With...
Source: Roche Investor Update - July 29, 2021 Category: Pharmaceuticals Source Type: news

European agency clears Moderna vaccine for children 12-17
The European Medicines Agency has recommended clearing Moderna’s COVID-19 vaccine for children ages 12 to 17, the first time the shot has been authorized for people under 18 (Source: ABC News: Health)
Source: ABC News: Health - July 23, 2021 Category: Consumer Health News Tags: Health Source Type: news

The European Medicines Agency recommends approving Moderna’s COVID-19 vaccine for children aged 12 to 17
The European Medicines Agency recommends approving Moderna’s COVID-19 vaccine for children aged 12 to 17 (Source: ABC News: Health)
Source: ABC News: Health - July 23, 2021 Category: Consumer Health News Tags: Health Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

European Medicines Agency grants Orphan Drug Designation to Zydus Cadila's Saroglitazar Mg
Orphan Drug status in Europe is given to medicines with the potential to be safe and effective treatments for rare, life-threatening, or chronically debilitating conditions affecting no more than 5 people in 10,000 people. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 21, 2021 Category: Pharmaceuticals Source Type: news

EU likely to decide on Moderna COVID shot for kids next week
A top official at the European Medicines Agency says a decision on whether to recommend that Moderna’s COVID-19 vaccine be authorized for children is expected late next week (Source: ABC News: Health)
Source: ABC News: Health - July 15, 2021 Category: Consumer Health News Tags: Health Source Type: news

Johnson & Johnson Statement on COVID-19 Vaccine (7/12)
NEW BRUNSWICK, N.J., July 12, 2021 – The safety and well-being of the people who use our products is our number one priority. Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. While the chance of having this occur is very low, Johnson & Johnson has updated its COVID-19 Vaccine Factsheet to include important information about these rare cases and on the signs and symptoms of Guillain-Barré syndrome. Updates with this new information will be implemented in other regions...
Source: Johnson and Johnson - July 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Africa: Discriminatory EU Vaccines Passport Mark of Duplicity
[Capital FM] A plan by the European Union not to recognize Covid-19 vaccines manufactured outside the block could set back global efforts to contain the pandemic. The intended vaccines passport by the EU risks leaving out travelers from developing countries who have largely received vaccines made outside the EU and the US. What is more appalling is that some EU member states have been actively donating vaccines not recognized by the European Medicines Agency to poor countries such as the Covishield. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 5, 2021 Category: African Health Source Type: news

Delta Variant Not Driving Hospitalization Surge in England, Data Shows
Although the number of coronavirus infections has risen sharply in recent weeks, hospitalization rates remain low. (Source: NYT Health)
Source: NYT Health - July 1, 2021 Category: Consumer Health News Authors: Emily Anthes Tags: Disease Rates Vaccination and Immunization Coronavirus (2019-nCoV) England European Medicines Agency Source Type: news

Serum Institute confident of European drug regulator nod for Covishield in a month
Poonawalla said SII has applied to the European Medicines Agency (EMA) through AstraZeneca. "The process has to take its time. An approval process even with UK MHRA, WHO took its time and we have applied to the EMA," he said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 1, 2021 Category: Pharmaceuticals Source Type: news

Covid-19: Double doses of vaccine seems to curb Delta variant, says European Medicines Agency
(Source: The Economic Times)
Source: The Economic Times - July 1, 2021 Category: Consumer Health News Source Type: news

EU-approved COVID-19 vaccines protect against Delta variant, says official
"There have been a number of variants over the last months and we expect more," said Marco Cavaleri, European Medicines Agency's (EMA) head of vaccine strategy, during a press briefing. (Source: The Economic Times)
Source: The Economic Times - July 1, 2021 Category: Consumer Health News Source Type: news

EU Green Light for Roxadustat in Anemia of Kidney Disease EU Green Light for Roxadustat in Anemia of Kidney Disease
European Medicines Agency committee issues a positive opinion for roxadustat, which would be the first orally administered treatment for adults with CKD-associated anemia.International Approvals (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 29, 2021 Category: Transplant Surgery Tags: Nephrology News Alert Source Type: news

Serum Institute asks govt to take up inclusion of Covishield in EU vaccination passport
Only four vaccines -- Comirnaty of Pfizer/BioNTech, Moderna, Vaxzervria by AstraZeneca-Oxford and, Johnson& Johnson's Janssen -- have been approved by the European Medicines Agency (EMA). Only those inoculated with these vaccines will be given vaccination passports and allowed to travel within the EU during the pandemic. (Source: The Economic Times)
Source: The Economic Times - June 28, 2021 Category: Consumer Health News Source Type: news

Moderna seeks approval for giving its Covid vaccine to children in Europe
Covid-19 vaccine maker Moderna has asked the European Medicines Agency for permission to give its jab to children aged between 12 and 17. (Source: the Mail online | Health)
Source: the Mail online | Health - June 7, 2021 Category: Consumer Health News Source Type: news

The Latest: Moderna seeks to use vaccine for adolescents
Moderna Inc. has filed a request with the European Medicines Agency for its COVID-19 vaccine to be granted authorization for use in adolescents (Source: ABC News: Health)
Source: ABC News: Health - June 7, 2021 Category: Consumer Health News Tags: Health Source Type: news

France planning to inject 12-year-old children with spike protein bioweapons
(Natural News) The President of France, Emmanuel Macron, recently announced the government’s plan to prey on psychologically vulnerable parents and vaccinate as many children as possible. Children as young as 12 years of age will be pressured to inoculate with experimental spike proteins from the Pfizer-BioNTech vaccine series. The European Medicines Agency recently approved the... (Source: NaturalNews.com)
Source: NaturalNews.com - June 4, 2021 Category: Consumer Health News Source Type: news